May Mabro

Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study

Benoist Chibaudel, Frédérique Maindrault‐Gœbel, Gérard Lledo et al. · Journal of Clinical Oncology · 2009 · 394 citations

CPT-11 (Irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer

Thierry André, Christophe Louvet, F. Maindrault-Gœbel et al. · European Journal of Cancer · 1999 · 268 citations

Oncology, Gastrointestinal Oncology, Medicine +8

Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial

Thierry André, Déwi Vernerey, Laurent Mineur et al. · Journal of Clinical Oncology · 2018 · 169 citations

Dfs Events, Surgical Oncology, Oncology +14

Risk factors for Coronavirus Disease 2019 (COVID-19) severity and mortality among solid cancer patients and impact of the disease on anticancer treatment: A French nationwide cohort study (GCO-002 CACOVID-19)

Astrid Lièvre, Anthony Turpin, Isabelle Ray‐Coquard et al. · European Journal of Cancer · 2020 · 163 citations · Full text

Solid Cancer Patients, Cancer Epidemiology, Disease Risk Assessment +12

High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)

F. Maindrault-Gœbel, Aimery de Gramont, Christophe Louvet et al. · European Journal of Cancer · 2001 · 147 citations

High-dose Intensity Oxaliplatin, Medicine, Pharmacology +7